Hemostemix Inc. announced that Stem Cell Research & Therapy published the Company's seventh peer reviewed study of ACP-01 - the third peer reviewed study of ACP the third peer reviewed study ofACP-01 as a treatment for heart disease (ischemic and non-ischemic dilated cardiomyopathy), which demonstrates ACP-01 regenerates and improves cardiac function by up to 24.1% at 12 months in ischemic cardiomyopathy, and regenerates and improves cardiac function in non-ischemic cardiomyopathy patients by up to 47.1% at 12 months (dLVEF%/iLVEF%). Cardiomyopathy is chronic disease of heart muscle due to an acquired or hereditary condition. This study was not prospective and randomized.

However, in the context of 2 previous studies of cardiomyopathy patients who underwent implantation of ACP-01 on a compassionate use basis, the signiYicant results of this study provides a compelling impetus to proceed with a Phase 2 randomised, prospective trial of ACP-01 for treatment of ischemic and non-ischemic dilutedated cardiomyopthy. Methods: This IRB approved outcome analysis reports upon 74 consecutive patients who failed medical management for severe cardiomyopathy, and were selected to undergo transcatheter intramyocardial or intracoronary implantation of ACP-1. This is third peer reviewed study of heart disease (41, 106 and 53 heart patients, respectively). Completed by three independent teams, each study confirms ACP-01 is a breakthrough treatment for ischemic and non ischemic cardiomyopthy.